ATG9B and central nervous system cancer: Regardless of the mRNA or protein level, the patients in the ASCL2‐ATG9B axisHigh group exhibited poorer prognosis than the other 2 groups, which indicated that the ASCL2‐ATG9B axis could be a prognostic marker in gliomas (Figure 5C,D).